Sanjay  Subramanian net worth and biography

Sanjay Subramanian Biography and Net Worth

CFO of Ocugen
Mr. Subramanian brings more than 20 years' experience in finance and operations strategy, serving most recently as CFO for a public company, Aralez Pharmaceuticals. He joined Aralez's finance leadership team at its inception, helped the company close $350M in financing and took on increasing responsibilities culminating as the CFO. Prior to that, he held leaderships position at Bausch Health Companies and General Motors, including serving as the Managing Director at its Korea division. Mr. Subramanian is an experienced leader in corporate finance, capital markets, business development and M&A. He holds an MBA from MIT Sloan School of Management, a Master of Science from MIT and The Ohio State University and a Bachelor of Technology from Indian Institute of Technology.

What is Sanjay Subramanian's net worth?

The estimated net worth of Sanjay Subramanian is at least $121,916.43 as of July 15th, 2021. Mr. Subramanian owns 76,677 shares of Ocugen stock worth more than $121,916 as of April 16th. This net worth approximation does not reflect any other assets that Mr. Subramanian may own. Learn More about Sanjay Subramanian's net worth.

How do I contact Sanjay Subramanian?

The corporate mailing address for Mr. Subramanian and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Sanjay Subramanian's contact information.

Has Sanjay Subramanian been buying or selling shares of Ocugen?

Sanjay Subramanian has not been actively trading shares of Ocugen within the last three months. Most recently, Sanjay Subramanian sold 10,000 shares of the business's stock in a transaction on Tuesday, October 26th. The shares were sold at an average price of $11.07, for a transaction totalling $110,700.00. Learn More on Sanjay Subramanian's trading history.

Who are Ocugen's active insiders?

Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Are insiders buying or selling shares of Ocugen?

In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 200,278 shares worth more than $100,139.00. The most recent insider tranaction occured on June, 14th when Director Junge Zhang bought 200,278 shares worth more than $100,139.00. Insiders at Ocugen own 3.5% of the company. Learn More about insider trades at Ocugen.

Information on this page was last updated on 6/14/2023.

Sanjay Subramanian Insider Trading History at Ocugen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/26/2021Sell10,000$11.07$110,700.00View SEC Filing Icon  
10/15/2021Sell7,990$9.96$79,580.40View SEC Filing Icon  
7/15/2021Sell31,086$6.70$208,276.2076,677View SEC Filing Icon  
6/15/2021Sell31,000$7.00$217,000.0076,591View SEC Filing Icon  
5/14/2021Sell31,000$8.18$253,580.0076,591View SEC Filing Icon  
4/29/2021Sell7,990$10.98$87,730.2053,581View SEC Filing Icon  
11/22/2019Buy5,000$0.28$1,400.0010,000View SEC Filing Icon  
10/2/2019Buy5,000$1.88$9,400.00
See Full Table

Sanjay Subramanian Buying and Selling Activity at Ocugen

This chart shows Sanjay Subramanian's buying and selling at Ocugen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ocugen Company Overview

Ocugen logo
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $1.59
Low: $1.52
High: $1.60

50 Day Range

MA: $1.16
Low: $0.52
High: $1.88

2 Week Range

Now: $1.59
Low: $0.35
High: $2.11

Volume

2,980,150 shs

Average Volume

8,161,378 shs

Market Capitalization

$407.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.51